research (163) Cutting Costs, Not Care: New Models for Affordable Men’s Health Medications
Using Mark Cuban Cost Plus Drug Company can save money on men's health medications compared to Medicare.
Search
for
Sort by
Research
30 / 1000+ resultsresearch Cutting Costs, Not Care: New Models for Affordable Men’s Health Medications
CPDC offers significant cost savings on men's health medications compared to Medicare and GoodRx.
research Urological Drug Price Stewardship: Potential Cost Savings Based on the Mark Cuban Cost Plus Drug Company Model
Adopting the Mark Cuban Cost Plus Drug Company pricing model could save Medicare about $1.29 billion on urological drugs.
research Discount pharmacies may save patients significant money on androgenetic alopecia medications compared to both traditional pharmacies and direct-to-consumer companies
Discount pharmacies offer cheaper options for hair loss medications than traditional or direct-to-consumer pharmacies.
research PD14-05 ECONOMIC IMPLICATIONS OF UROLOGIST PRESCRIPTION PRACTICES AMONG MEDICARE PART D BENEFICIARIES
Using more low-cost and generic drugs could save Medicare Part D a lot of money.
research Editorial Comment
Generic drugs for benign prostatic hyperplasia can cost up to 500% more at chain pharmacies compared to independent ones.
research Direct-to-consumer Androgenetic Alopecia treatments: A Cost Comparison with traditional pharmacies
research Cross-Sectional Cost Analysis of Finasteride for Androgenetic Alopecia via Direct-to-Consumer Pharmacies Compared to Online Wholesale Pharmacies
research The High Cost of Health Care: Why Some Pay $240 for a $9 Bottle of Pills
Some people pay $240 for medication that costs $9 due to drug industry tactics and complicated healthcare policies.
research Finasteride plus doxazosin combination tops in BPH
research Cost effectiveness of finasteride: a risky business?
research New product intros (finasteride/tadalafil (new combination); sutimlimab; human SARS-CoV-2 recombinant nanoparticle vaccine, adjuvanted with AS03; bupropion hydrochloride/dextromethorphan hydrobromide (new combination))
research American College of Clinical Pharmacology Twenty‐Second Annual Meeting November 1–3, 1993 Boston, Massachusetts
research 44249 Financing Finasteride: Identifying Resources to Improve Access
GoodRx.com helps find the cheapest options for finasteride, a medication not often covered by insurance.
research DrugNet: Network-based drug–disease prioritization by integrating heterogeneous data
DrugNet effectively identifies new uses for existing drugs and may save resources in drug development.
research Price Discrimination Across Indications in the Pharmaceutical Industry: The Case of Finasteride
Proscar and Propecia, two drugs with the same ingredient but different dosages, have different prices, showing price discrimination in the pharmaceutical industry.
research PSS36 ECONOMIC ANALYSIS OF CATARACT SURGERY IN EUROPE:AN ANALYSIS OF HOSPITAL DATABASES AVAILABLE IN 11 COUNTRIES
Cataract surgery in Europe varies in frequency and cost between countries.
research Finasteride
research Finasteride
research Cost-minimization Analysis of 2 Drug Therapy Projects Including Traditional Chinese Medcines and Chemical Medcines in BPH Patients
Qianliekang and liuweidihuangwan are cheaper for BPH treatment than finasteride and tamsulosin.
research A Need for Government Intervention? Prescription Drug Prices and Retail Mark-Ups
Government action is needed to address high prescription drug prices.
research Lifestyle Drugs
The article concludes that a balance is needed between individual healthcare needs and societal resources when it comes to lifestyle drugs, with a call for compassionate policy application.
research MP27-18 STATEWIDE GEOGRAPHIC PRICE VARIATION OF GENERIC BPH MEDICATIONS
Big chain pharmacies in Pennsylvania charge significantly more for generic BPH medications than independent pharmacies, but independent pharmacies have more regional price variation.
research Identification of Established Drugs for Contemporary Indications: A Hospital Based Study
Drug repurposing can be cost-effective but needs more testing for safety and effectiveness.
research Additional Benefit Scoring During Health Technology Assessment in Germany - Its Drivers and Impact on Pricing and Discount for Orphan Drugs
Orphan drug benefit scores in Germany are influenced by phase III data and lack of alternatives, but not linked to price or discounts.
research Sometimes Marketing Efforts by Advocacy Organizations Can Lose Touch with the Nuances of Appropriateness
Advocacy groups should avoid marketing partnerships that may imply drug endorsements.
research Spectrum and signals of medication-associated cognitive disorder: a comprehensive disproportionality analysis with cross-database validation
Many medications may be linked to cognitive disorders, but most lack warnings on labels.
research The Osler Lecture 2012 'Pharmacology 2.0, medicines, drugs and human enhancement'
The lecture concluded that drugs for human enhancement are here to stay and called for their responsible development and fair access.
research Health Canada has approved finasteride [Proscar; Merck Frosst] and doxazosin cotherapy
research The switch from patented medicine to the generic one: an option or a necessity?
Switching to generic drugs is necessary but faces communication and information challenges.